Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 14, 2007; 13(22): 3137-3140
Published online Jun 14, 2007. doi: 10.3748/wjg.v13.i22.3137
Published online Jun 14, 2007. doi: 10.3748/wjg.v13.i22.3137
Table 1 Main characteristics and course of HCV-infected patients with VKH-like disease
Case 1 | Case 2 | Case 3 | |
Age (yr) | 43 | 51 | 42 |
Sex | F | F | M |
HCV genotype liver biopsy (Metavir)1 | 3 | 1 | 1 |
A1F2 | A1F2 | A3F1 | |
Anti-HCV therapy | PEG-IFN α-2b + Ribavirin | PEG-IFN α-2b + Ribavirin | PEG-IFN α-2b + Ribavirin |
Interval before first ocular manifestations2 | 4 mo | 3 mo | 4 mo |
Ocular manifestations | -Visual acuity 20/200 OS | -Bilateral vision loss | -Bilateral vision loss |
-Macular edema and a bilateral serous retinal detachment. | -Bilateral uveitis, major papillar and retinal edema | -Episcleritis and bilateral uveitis | |
Retinal fluorescein angiography | Pin-points and bilateral serous retinal and pigmented epithelium detachments, suggestive of a Vogt-Koyanagi-Harada like [VKH] disease | ||
Therapeutic management | -PEG-IFN and ribavirin disruption | -PEG-IFN and ribavirin disruption | -PEG-IFN and ribavirin disruption |
-Methylprednisolone IV and per os | - Methylprednisolone IV and per os | - Methylprednisolone IV and per os | |
Course | -Complete recovery under low dose steroids (< 10 mg/d) | -Low improvement of ocular lesions | -Partial improvement of ocular lesions |
-Steroids were stopped after one year of treatment without ocular relapse. | -Cortico-dependency > 25 mg/d | -Cortico-dependency > 25 mg/d | |
-Failure of cyclosporine course | -Re-introduction of PEG-IFN and ribavirin 5 mo later3 | ||
-Introduction of azathioprine | -Full recovery of ocular manifestations 10 mo after IFN was reintroduced |
Table 2 Main features of HCV-infected patients with intraocular vascular complications under PEG-IFN and ribavirin treatment
Main features | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 |
Age (yr) | 51 | 70 | 55 | 40 | 40 |
Sex | M | M | F | M | M |
HCV genotype | 1 | 2 | |||
Liver biopsy (Metavir) | ND | F4 | A2F1 | A2F2 | F4 (clinical cirrhosis) |
Antecedents | Sarcoidosis | Arterial hypertension | - | Splenic lymphoma with villous lymphocytes | Hypertension with past hypertensive retinopathy |
Smoking | Mixed cryoglobulin- associated glomerulonephritis | ||||
Severe arterial hypertension | |||||
Dyslipidemia, smoking | |||||
Anti-HCV therapy | PEG-IFN α-2b + Ribavirin | PEG-IFN α-2b + Ribavirin | PEG-IFN α-2b + Ribavirin | Standard IFN α-2b + ribavirin | Standard IFN α-2b + Ribavirin |
Interval before first ocular manifestations | 7 mo | 5 mo | 6 mo | 18 mo | 6 mo |
Ocular manifestations | -Initial visual acuity: OD (< 20/200), OS (20/20) | -OD vision loss (20/200 OD; 20/20 OS) | -Bilateral vision loss (20/400 OD, 20/80 OS) | -Visual acuity OS: 10/10; OD: < 20/200 | -Bilateral vision loss (20/64 P2 OD, 20/200 OS) |
-Papillar edema, macular edema and retinal hemorrhages | -Bilateral macular edema and retinal hemorrhages | ||||
-Cotton wool spots | -Cotton-wool spots (IFN-α-induced retinopathy) (Figure 1A and B) | ||||
Diagnosis | Central retinal vein occlusion OD | Central retinal vein occlusion OD | Acute anterior ischemic optic neuritis | Central retinal artery occlusion OD | Exsudative hypertensive and IFN -induced retinopathy |
Treatment | -Withdrawal of PEG-IFN and ribavirin | -Withdrawal of PEG-IFN and ribavirin | -Withdrawal of PEG-IFN and ribavirin | -Withdrawal of standard IFN and ribavirin | -Withdrawal of standard IFN and ribavirin |
-Steroids and IV heparin | -Steroids, IV heparin and aspirin | -Steroids | -Steroids and IV heparin | -Better control of hypertension (nadolol, benazepril) | |
Course | -6 mo later, radiary neurotomy | -2 mo later, radiary neurotomy | -At the end of follow-up, severe visual impairment (< 20/400 OD; 20/80 OS) | -4 mo later, slow improvement (20/64 OD) | -2 mo later, significant improvement of the visual acuity (20/40 OD; 20/40 OS) |
-At the end of follow-up, definitive loss of vision OD (< 20/200) | -At the end of follow-up, definitive vision loss OD | -Died of severe sepsis 5 mo later | -Introduction of PEG- IFN α-2b and Ribavirin without recurrence after more than 1 yr follow-up |
- Citation: Sène D, Touitou V, Bodaghi B, Saadoun D, Perlemuter G, Cassoux N, Piette JC, Hoang PL, Cacoub P. Intraocular complications of IFN-α and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13(22): 3137-3140
- URL: https://www.wjgnet.com/1007-9327/full/v13/i22/3137.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i22.3137